Abstract：A boy, aged 66 days, was admitted to the hospital due to subcutaneous nodules for 46 days and abdominal distension for 10 days. The main clinical manifestations were loss of adipose tissue, subcutaneous nodules, insulin-resistant diabetes, hypertriglyceridemia, and hepatic steatosis. The boy was diagnosed with congenital generalized lipodystrophy type 1 (CGL1). His condition was improved after administration of middle-chain fatty acid formula milk and insulin injection or oral metformin. Gene testing revealed a homozygous mutation, c.646A > T, in the AGPAT2 gene, and both his parents were carriers of this mutation. This case of CGL1 has the youngest age of onset ever reported in China and multiple subcutaneous nodules as the initial symptom.
Grulich-Henn J, Wagner V, Thon A, et al. Entities and frequency of neonatal diabetes:data from the diabetes documentation and quality management system (DPV)[J]. Diabet Med, 2010, 27(6):709-712.
[2]
Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes mellitus:an update on diagnosis and management[J]. Clin Perinatol, 2018, 45(1):41-59.
[3]
Russo L, Iafusco D, Brescianini S, et al. Permanent diabetes during the first year of life:multiple gene screening in 54 patients[J]. Diabetologia, 2011, 54(7):1693-1701.
[4]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[5]
Akinci B, Onay H, Demir T, et al. Natural history of congenital generalized lipodystrophy:a nationwide study from Turkey[J]. J Clin Endocrinol Metab, 2016, 101(7):2759-2767.
[6]
Lima JG, Nobrega LH, de Lima NN, et al. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy[J]. Diabetol Metab Syndr, 2016, 8:23.
[7]
Patni N, Garg A. Congenital generalized lipodystrophies-new insights into metabolic dysfunction[J]. Nat Rev Endocrinol, 2015, 11(9):522-534.
[8]
Garg A. Acquired and inherited lipodystrophies[J]. N Engl J Med, 2004, 350(12):1220-1234.
[9]
Liu Y, Li D, Ding Y, et al. Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants[J]. Eur J Med Genet, 2019, 62(9):103542.
[10]
Lima JG, Nobrega LHC, Lima NN, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy[J]. PLoS One, 2018, 13(6):e0199052.
[11]
Hussain I, Garg A. Lipodystrophy syndromes[J]. Endocrinol Metab Clin North Am, 2016, 45(4):783-797.
[12]
Garg A. Lipodystrophies[J]. Am J Med, 2000, 108(2):143-152.
[13]
Ceccarini G, Magno S, Pelosini C, et al. Congenital generalized lipoatrophy (Berardinelli-Seip syndrome) type 1:description of novel AGPAT2 homozygous variants showing the highly heterogeneous presentation of the disease[J]. Front Endocrinol (Lausanne), 2020, 11:39.
[14]
Cautivo KM, Lizama CO, Tapia PJ, et al. AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue[J]. Mol Metab, 2016, 5(7):491-505.
[15]
Papendieck L, Araujo MB. Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy[J]. J Pediatr Endocrinol Metab, 2018, 31(1):77-83.
[16]
Tchang BG, Shukla AP, Aronne LJ. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives[J]. Expert Opin Biol Ther, 2015, 15(7):1061-1075.
[17]
Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes:the long-term Spanish experience[J]. Endocrine, 2015, 49(1):139-147.
[18]
Brown RJ, Oral EA, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy[J]. Endocrine, 2018, 60(3):479-489.
